Exact Sciences Announces Third Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
UBS Downgrades Exact Sciences (EXAS) to Neutral
October 29, 2020 6:11 AM EDTUBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from $125.00).
The analyst comments "We like the Thrive Deal on many levels, though timelines are lengthy & visibility limited. With COVID-19 pressuring the base business, plus... More
Exact Sciences (EXAS) Q3 Revenues Beat
October 27, 2020 7:10 AM EDTExact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($1.46), which may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $408.4 million versus the consensus estimate of $337.37 million. COVID-19 testing revenue was $102.2 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
... More